CG Oncology (CG Oncology) LT-Debt-to-Total-Asset : 0.00 (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is CG Oncology LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. CG Oncology's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.00.

CG Oncology's long-term debt to total assets ratio declined from Dec. 2022 (0.05) to Mar. 2024 (0.00). It may suggest that CG Oncology is progressively becoming less dependent on debt to grow their business.

CG Oncology LT-Debt-to-Total-Asset Historical Data

The historical data trend for CG Oncology's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology LT-Debt-to-Total-Asset Chart

CG Oncology Annual Data

Trend

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

0.21

0.05

CG Oncology Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial			0.05	-	-	-	-

CG Oncology LT-Debt-to-Total-Asset Calculation

CG Oncology's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	0.244	/	199.301
	=	0.00

CG Oncology's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	0.184	/	579.108
	=	0.00

CG Oncology (NAS:CGON) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

CG Oncology LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of CG Oncology's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

CG Oncology (CG Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

CG Oncology (CG Oncology) Headlines

From GuruFocus

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

By Marketwired • 04-24-2024